NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma.

Jeker, Barbara; Novak, Urban; Mansouri Taleghani, Behrouz; Baerlocher, Gabriela M.; Seipel, K; Mueller, B U; Bigler, M; Betticher, D; Luethi, J-M; Farese, S; Ruefer, A; Pabst, Thomas (2018). NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma. Bone marrow transplantation, 53(2), pp. 175-179. Nature Publishing Group 10.1038/bmt.2017.234

[img] Text
bmt2017234.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (219kB) | Request a copy

Chemotherapy with G-CSF is used to mobilize peripheral stem cells in multiple myeloma (MM) patients, with plerixafor as a rescue strategy for poorly mobilizing patients. Preclinical studies suggested that the nonsteroidal anti-inflammatory drug meloxicam enhances the mobilization of CD34+ cells. In this single-center study, we evaluated whether adding meloxicam to chemotherapy/G-CSF mobilization increases peripheral hematopoietic CD34+ cell levels and reduces the need of using plerixafor. We prospectively compared two consecutive cohorts of MM patients in first remission mobilized with G-CSF and non-myelosuppressive chemotherapy with vinorelbine or gemcitabine. The second cohort additionally received oral meloxicam. The cohorts comprised 84 patients without meloxicam (-M) and 66 patients with meloxicam (+M). Meloxicam was well tolerated and associated with similar hematologic engraftment after transplantation and equal survival rates. However, the meloxicam group had higher CD34+ cell levels on day 8 of the mobilization procedure (53 200 versus 35 600 CD34+ cells/mL; P=0.007), and fewer patients needed >1 collection day (+M: 6 (9%) patients versus -M: 16 (19%) patients; P=0.04). This resulted in reduced plerixafor administrations (+M: 7 (11%) patients versus -M: 18 (21%) patients; P=0.03) and less costs. Our data suggest that meloxicam enhances the mobilization of hematopoietic CD34+ blood cells in MM patients.Bone Marrow Transplantation advance online publication, 23 October 2017; doi:10.1038/bmt.2017.234.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene)

UniBE Contributor:

Jeker, Barbara; Novak, Urban; Mansouri Taleghani, Behrouz; Baerlocher, Gabriela M. and Pabst, Thomas

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0268-3369

Publisher:

Nature Publishing Group

Language:

English

Submitter:

Katrin Kölliker-Schütz

Date Deposited:

07 Feb 2018 12:32

Last Modified:

09 Feb 2018 16:14

Publisher DOI:

10.1038/bmt.2017.234

PubMed ID:

29058701

BORIS DOI:

10.7892/boris.110109

URI:

https://boris.unibe.ch/id/eprint/110109

Actions (login required)

Edit item Edit item
Provide Feedback